NJ-ACS Mass Spec Discussion Group

The NJ Mass Spectrometry Discussion Group presents its November meeting on Wednesday, November 11, 2015 at at the Holiday Inn Somerset-Bridgewater, 195 Davidson Ave, Somerset NJ 08873 [ hotel website ]

Sponsored by Shimadzu

The evening is free for attendees, courtesy of our sponsor!

Please register here.


5:30 pm Social and registration

6:15 pm Complimentary dinner

7:00 pm Welcome and opening remarks

7:05 pm Speakers

Seminar Speakers

I. Ruth Verplaetse, PhD

Q2 (a Quintiles Quest Joint Venture)

Quantitative Determination of Opioids in Whole Bloodusing Fully Automated Dried Blood Spot DesorptionCoupled to On-line SPE-LC-MS/MS

II. Jeff Dahl, PhD

Application Scientist, Shimadzu Scientific Instruments

Shimadzu Technical Innovations and Collaborations in UFMS

ABSTRACT for Dr Verplaetse: Opioids are well known, widely used painkillers. Increased stability of opioids in the dried blood spot (DBS) matrix compared to blood/plasma has been described. Other benefits provided by DBS techniques include point-of-care collection, less invasive micro sampling, more economical shipment and convenient storage. Current methodology for analysis of micro whole blood samples for opioids is limited to the classical DBS workflow including tedious manual punching of the DBS cards followed by extraction and LC-MS/MS bioanalysis. The goal of this study was to develop and validate a fully automated on-line sample preparation procedure for the analysis of DBS micro samples relevant to the detection of opioids in finger prick blood. To this end, automated flow-through elution of DBS cards was followed by on-line solid-phase extraction (SPE) and analysis by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Selective, sensitive, accurate and reproducible quantitation of five representative opioids in human blood at sub-therapeutic, therapeutic and toxic levels was achieved. The range of reliable response (R2 ≥0.997) was 1 to 500 ng/mL whole blood for morphine, codeine, oxycodone, hydrocodone and 0.1 to 50 ng/mL for fentanyl. Inter-day, intra-day and matrix inter-lot accuracy and precision was less than 15% (even at LLOQ level). The method was successfully used to measure hydrocodone and its major metabolite norhydrocodone in incurred human samples. Our data support the enormous potential of DBS sampling and automated analysis for monitoring opioids as well as other pharmaceuticals in both anti-doping and pain management regimens.